Early phase drug development is a complex process, where many moving parts can, and do, influence the success of a program. Managing multiple vendors for preclinical, manufacturing, bioanalysis, and early phase clinical trials doesn’t need to be an additional challenge — engaging with a single partner who seamlessly and proactively advances your projects through the critical early stages, can make all the difference.
Given the high cost of drug development, and modest percentage of drugs that make it to final market approval, maximizing the efficiency of an early phase program is essential. Altasciences’ integrated, full‑service capabilities, supported by comprehensive research support services, can make the process seamless and efficient. Having a single‑source vendor reduces the administrative burden of multiple vendor agreements, reduces handoffs and the challenge of managing timelines across suppliers, simplifies communication and planning, and ultimately delivers a more synchronized experience.
The Benefits of Proactive Drug Development
At Altasciences, we champion Proactive Drug Development. This innovative approach aligns our decades of expertise around delivering a streamlined, synchronized early phase drug development pathway, supported by specially designed systems, processes, and a unique organizational structure, at every step.
A dedicated, cross-functional program manager is your main point of contact. They use our proprietary scheduling system to manage your program timelines from API availability to final commercialization. Program management is supported by a fully transparent information sharing system (Tell Us Once™/Ask Albert) that ensures all key stakeholders have visibility on your studies, programs, and preferences, and adjust their work plans, as your project advances.
As a full service CRO/CDMO vendor, openly sharing information and proactively supporting decision-making in real time, we are not limited by a linear, task-based approach. For example, we can update your Investigational Brochure while your IND‑enabling studies are in progress. The synchronization and communication allow us to plan your clinical program while your preclinical safety assessment is ongoing, and you can start first‑in‑human (FIH) trials as soon as you receive regulatory approval.
We facilitate quick start-up of FIH trials by timing small-scale drug formulations with clinical conduct, and make rapid, informed dosing decisions based on timed bioanalytical analysis and safety data.
When project decisions are informed by concrete data, received in real-time, and analyzed by a knowledgeable, highly skilled team of experts, timelines can be reduced by as much as 40%.
Structural Support for Smooth Integration
Altasciences fosters complete integration of all our services at a grassroots level, eliminating the internal silos that can impact your timelines. This group of forward-thinkers and scientific experts become extensions of your team, dedicated to advancing your studies.
Scientific and operational teams are led by only two executives to ensure that we deliver both horizontal and vertical integration across departments, locations, and specialty areas. We are aligned around a common objective, to deliver high quality data for the studies and programs entrusted to us.
- Innovation in the pharmaceutical industry: New estimates of R&D costs. Link: https://www.sciencedirect.com/science/article/abs/pii/S0167629616000291
- A Tough Road: Cost To Develop One New Drug Is $2.6 Billion; Approval Rate for Drugs Entering Clinical Development is Less Than 12%